{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T02:47:08Z","timestamp":1773283628894,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Critical Care"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jcrc.2024.154991","type":"journal-article","created":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T01:57:22Z","timestamp":1734400642000},"page":"154991","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["A retrospective Cohort study on the effect of the LOw-molecular weighT heparin (LMWH) nadroparin dose on anti-XA levels in a mixed medical-surgical ICU population: CLOT-Xa"],"prefix":"10.1016","volume":"86","author":[{"given":"Lisanne","family":"van Berkel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marnix","family":"Kuindersma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid D.","family":"van Iperen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henk J.","family":"Adriaansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janine J.J.","family":"Hulstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter E.","family":"Spronk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jcrc.2024.154991_bb0005","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.injury.2019.10.066","article-title":"The ATLANTIC study: anti-Xa level assessment in trauma intensive care","volume":"51","author":"Rakhra","year":"2020","journal-title":"Injury"},{"issue":"5","key":"10.1016\/j.jcrc.2024.154991_bb0010","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1378\/chest.15-0287","article-title":"VTE incidence and risk factors in patients with severe Sepsis and septic shock","volume":"148","author":"Kaplan","year":"2015","journal-title":"Chest"},{"issue":"23","key":"10.1016\/j.jcrc.2024.154991_bb0015","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000015833","article-title":"The cumulative venous thromboembolism incidence and risk factors in intensive care patients receiving the guideline-recommended thromboprophylaxis","volume":"98","author":"Zhang","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jcrc.2024.154991_bb0020","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1186\/s13054-015-1003-9","article-title":"Venous thromboembolism in the ICU: main characteristics, diagnosis and thromboprophylaxis","volume":"19","author":"Minet","year":"2015","journal-title":"Crit Care"},{"issue":"9309","key":"10.1016\/j.jcrc.2024.154991_bb0025","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(02)07920-5","article-title":"Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors","volume":"359","author":"D\u00f6rffler-Melly","year":"2002","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jcrc.2024.154991_bb0030","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/CCM.0000000000000713","article-title":"Failure of anticoagulant thromboprophylaxis: risk factors in medical-surgical critically ill patients*","volume":"43","author":"Lim","year":"2015","journal-title":"Crit Care Med"},{"issue":"2","key":"10.1016\/j.jcrc.2024.154991_bb0035","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.chest.2021.08.050","article-title":"VTE prophylaxis in critically ill adults: a systematic review and network meta-analysis","volume":"161","author":"Fernando","year":"2022","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.jcrc.2024.154991_bb0040","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0049-3848(02)00028-2","article-title":"Antifactor Xa activity in intensive care patients receiving thromboembolic prophylaxis with standard doses of enoxaparin","volume":"105","author":"Mayr","year":"2002","journal-title":"Thromb Res"},{"issue":"11","key":"10.1016\/j.jcrc.2024.154991_bb0045","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1001\/jamasurg.2016.1662","article-title":"Association between enoxaparin dosage adjusted by anti-factor Xa trough level and clinically evident venous thromboembolism after trauma","volume":"151","author":"Ko","year":"2016","journal-title":"JAMA Surg"},{"issue":"2","key":"10.1016\/j.jcrc.2024.154991_bb0050","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1001\/jamasurg.2017.3787","article-title":"Association of anti-factor Xa-guided dosing of enoxaparin with venous thromboembolism after trauma","volume":"153","author":"Karcutskie","year":"2018","journal-title":"JAMA Surg"},{"issue":"8","key":"10.1016\/j.jcrc.2024.154991_bb0055","doi-asserted-by":"crossref","first-page":"917","DOI":"10.5005\/jp-journals-10071-23879","article-title":"Factor Xa levels in patients receiving prophylactic enoxaparin sodium in the intensive care unit of an academic hospital","volume":"25","author":"Baloo","year":"2021","journal-title":"Indian J Crit Care Med"},{"issue":"2","key":"10.1016\/j.jcrc.2024.154991_bb0060","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.amjsurg.2017.07.014","article-title":"Anti-factor Xa measurements in acute care surgery patients to examine enoxaparin dose","volume":"216","author":"Wall","year":"2018","journal-title":"Am J Surg"},{"issue":"11","key":"10.1016\/j.jcrc.2024.154991_bb0065","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1111\/jth.14578","article-title":"Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation","volume":"17","author":"Iba","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"5","key":"10.1016\/j.jcrc.2024.154991_bb0070","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/ajhp\/zxab380","article-title":"The pathophysiology of sepsis-2021 update: part 1, immunology and coagulopathy leading to endothelial injury","volume":"79","author":"Jacobi","year":"2022","journal-title":"Am J Health Syst Pharm"},{"issue":"5","key":"10.1016\/j.jcrc.2024.154991_bb0075","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1055\/s-2001-17961","article-title":"How and when to monitor a patient treated with low molecular weight heparin","volume":"27","author":"Boneu","year":"2001","journal-title":"Semin Thromb Hemost"},{"issue":"2","key":"10.1016\/j.jcrc.2024.154991_bb0080","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1097\/TA.0000000000003580","article-title":"Relationship between anti-Xa level achieved with prophylactic low-molecular weight heparin and venous thromboembolism in trauma patients: a systematic review and meta-analysis","volume":"93","author":"Verhoeff","year":"2022","journal-title":"J Trauma Acute Care Surg"},{"key":"10.1016\/j.jcrc.2024.154991_bb0085","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ijsu.2018.01.023","article-title":"Trauma patients with lower extremity and pelvic fractures: should anti-factor Xa trough level guide prophylactic enoxaparin dose?","volume":"51","author":"Dhillon","year":"2018","journal-title":"Int J Surg"},{"issue":"4","key":"10.1016\/j.jcrc.2024.154991_bb0090","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/jcpt.13169","article-title":"The effect of anti-Xa monitoring on the safety and efficacy of low-molecular-weight heparin anticoagulation therapy: a systematic review and meta-analysis","volume":"45","author":"Wu","year":"2020","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.jcrc.2024.154991_bb0095","series-title":"Antithrombotic Drugs","author":"Ji","year":"2009"},{"issue":"4","key":"10.1016\/j.jcrc.2024.154991_bb0100","first-page":"874","article-title":"Standard prophylactic enoxaparin dosing leads to inadequate anti-Xa levels and increased deep venous thrombosis rates in critically ill trauma and surgical patients","volume":"68","author":"Malinoski","year":"2010","journal-title":"J Trauma"},{"issue":"4","key":"10.1016\/j.jcrc.2024.154991_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.100185","article-title":"The right time to measure anti-Xa activity in critical illness: pharmacokinetics of therapeutic dose nadroparin","volume":"7","author":"Sytema","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"2","key":"10.1016\/j.jcrc.2024.154991_bb0110","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/TA.0000000000000087","article-title":"Effect of a dalteparin prophylaxis protocol using anti-factor Xa concentrations on venous thromboembolism in high-risk trauma patients","volume":"76","author":"Droege","year":"2014","journal-title":"J Trauma Acute Care Surg"},{"issue":"6","key":"10.1016\/j.jcrc.2024.154991_bb0115","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1177\/000313481808400672","article-title":"Improving pharmacologic prevention of VTE in trauma: IMPACT-IT QI project","volume":"84","author":"Bethea","year":"2018","journal-title":"Am Surg"},{"issue":"5","key":"10.1016\/j.jcrc.2024.154991_bb0120","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.injury.2016.10.039","article-title":"Goal directed enoxaparin dosing provides superior chemoprophylaxis against deep vein thrombosis","volume":"48","author":"Kopelman","year":"2017","journal-title":"Injury"},{"key":"10.1016\/j.jcrc.2024.154991_bb0125","article-title":"Anti-factor Xa activity is not associated with venous thromboembolism in critically ill patients receiving enoxaparin for thromboprophylaxis: a retrospective observational study","volume":"9","author":"Dibiasi","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"6","key":"10.1016\/j.jcrc.2024.154991_bb0130","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1345\/aph.1L194","article-title":"Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings","volume":"43","author":"Nutescu","year":"2009","journal-title":"Ann Pharmacother"},{"issue":"2","key":"10.1016\/j.jcrc.2024.154991_bb0135","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s40262-022-01202-6","article-title":"Low and highly variable exposure to prophylactic LMWH nadroparin in critically ill patients: back to the drawing board for prophylactic dosing?","volume":"62","author":"Diepstraten","year":"2023","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"10.1016\/j.jcrc.2024.154991_bb0140","doi-asserted-by":"crossref","first-page":"R93","DOI":"10.1186\/cc4952","article-title":"Anti-Xa activity after subcutaneous administration of dalteparin in ICU patients with and without subcutaneous oedema: a pilot study","volume":"10","author":"Rommers","year":"2006","journal-title":"Crit Care"},{"issue":"3","key":"10.1016\/j.jcrc.2024.154991_bb0145","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1159\/000522498","article-title":"COVID-19 coagulopathy: from pathogenesis to treatment","volume":"145","author":"Alnima","year":"2022","journal-title":"Acta Haematol"},{"key":"10.1016\/j.jcrc.2024.154991_bb0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.thromres.2020.07.035","article-title":"Anti Xa activity after high dose LMWH thrombosis prophylaxis in covid 19 patients at the intensive care unit","volume":"196","author":"Vlot","year":"2020","journal-title":"Thromb Res"},{"issue":"6","key":"10.1016\/j.jcrc.2024.154991_bb0155","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1111\/bcp.15208","article-title":"Effects of dalteparin on anti-Xa activities cannot be predicted in critically ill COVID-19 patients","volume":"88","author":"van der Heijden","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.jcrc.2024.154991_bb0160","doi-asserted-by":"crossref","first-page":"5844","DOI":"10.4081\/hr.2015.5844","article-title":"The anti-factor Xa range for low molecular weight heparin Thromboprophylaxis","volume":"7","author":"Wei","year":"2015","journal-title":"Hematol Rep"}],"container-title":["Journal of Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0883944124004787?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0883944124004787?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T17:53:44Z","timestamp":1740678824000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0883944124004787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":32,"alternative-id":["S0883944124004787"],"URL":"https:\/\/doi.org\/10.1016\/j.jcrc.2024.154991","relation":{},"ISSN":["0883-9441"],"issn-type":[{"value":"0883-9441","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A retrospective Cohort study on the effect of the LOw-molecular weighT heparin (LMWH) nadroparin dose on anti-XA levels in a mixed medical-surgical ICU population: CLOT-Xa","name":"articletitle","label":"Article Title"},{"value":"Journal of Critical Care","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcrc.2024.154991","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"154991"}}